Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Lung Cancer

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 63 articles: HTML format Text format

Single Articles

December 2011
1. SMIT EF , Socinski MA, Mullaney BP, Myrand SP, et al
   Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. DECOSTER L , Wauters I, Vansteenkiste JF
   Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. JALAL SI , Riggs HD, Melnyk A, Richards D, et al
   Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosi
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
4. HAYASHI H , Okamoto I, Morita S, Taguri M, et al
   Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. CLAREY J , Kao SC, Clarke SJ, Vardy J, et al
   The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2011
6. BRODOWICZ T , Ciuleanu T, Crawford J, Filipits M, et al
   Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   July 2011
7. SMITH CB , Nelson JE, Berman AR, Powell CA, et al
   Lung cancer physicians' referral practices for palliative care consultation.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. NG QS , Mandeville H, Goh V, Alonzi R, et al
   Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. STAHEL R , Thatcher N, Fruh M, Le Pechoux C, et al
   1st ESMO Consensus Conference in lung cancer; Lugano 2010: Small-cell lung cancer.
   Ann Oncol. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   June 2011
10. JANSSEN-HEIJNEN ML , Maas HA, Siesling S, Koning CC, et al
    Treatment and survival of patients with small-cell lung cancer: small steps forward, but not for patients >80.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. TIBALDI C , Giovannetti E, Tiseo M, Leon LG, et al
    Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
12. GAULER TC , Besse B, Mauguen A, Meric JB, et al
    Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. COUDERT B , Ciuleanu T, Park K, Wu YL, et al
    Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. FELIP E , Gridelli C, Baas P, Rosell R, et al
    Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
15. POWLES T , Kayani I, Blank C, Chowdhury S, et al
    The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.
    Ann Oncol. 2011;22:1041-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. LE PECHOUX C , Laplanche A, Faivre-Finn C, Ciuleanu T, et al
    Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-
    Ann Oncol. 2011;22:1154-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
17. REIMAN T , Lai R, Veillard AS, Paris E, et al
    Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. MANEGOLD C , van Zandwijk N, Szczesna A, Zatloukal P, et al
    A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
19. WILLIAM WN , Kim JS, Liu DD, Solis L, et al
    The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. BAGNARDI V , Rota M, Botteri E, Scotti L, et al
    Alcohol consumption and lung cancer risk in never smokers: a meta-analysis.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. OH SW , Myung SK, Park JY, Lee CM, et al
    Aspirin use and risk for lung cancer: a meta-analysis.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. BESSE B , Massard C, Haddad V, Andre F, et al
    ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.
    Ann Oncol. 2011;22:575-81.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
23. TANAKA F , Wada H, Fukui Y, Fukushima M, et al
    Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. BARLESI F , Gervais R, Lena H, Hureaux J, et al
    Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. BLUMENSCHEIN GR JR , Kabbinavar F, Menon H, Mok TS, et al
    A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. CAPPUZZO F , Camidge DR, Varella-Garcia M
    Is FISH floating or still swimming in the lung cancer ocean?
    Ann Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
27. LI X , Butts C, Fenton D, King K, et al
    Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. HORGAN AM , Bradbury PA, Amir E, Ng R, et al
    An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. SCHMITTEL A , Sebastian M, Fischer von Weikersthal L, Martus P, et al
    A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. NA II , Park JY, Kim KM, Cheon GJ, et al
    Significance of smoking history and FDG uptake for pathological N2 staging in clinical N2-negative non-small-cell lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. BIESMA B , Wymenga AN, Vincent A, Dalesio O, et al
    Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. FENG F , Xiang Y, Wan X, Geng S, et al
    Salvage combination chemotherapy with floxuridine, dactinomycin, etoposide, and vincristine (FAEV) for patients with relapsed/chemoresistant gestational trophoblastic neoplasia.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. RECK M , Kaiser R, Eschbach C, Stefanic M, et al
    A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. GRIDELLI C , Morgillo F, Favaretto A, de Marinis F, et al
    Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. GARASSINO MC , Marabese M, Rusconi P, Rulli E, et al
    Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.
    Ann Oncol. 2011;22:235-7.
    PubMed     Text format     Related articles   
    
    
    
    
36. TOURNOY KG , Govaerts E, Malfait T, Dooms C, et al
    Endobronchial ultrasound-guided transbronchial needle biopsy for M1 staging of extrathoracic malignancies.
    Ann Oncol. 2011;22:127-31.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
37. SORIA JC , Massard C, Le Chevalier T
    Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
    Ann Oncol. 2010;21:2324-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
38. GIOULBASANIS I , Baracos VE, Giannousi Z, Xyrafas A, et al
    Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. JANSSEN-HEIJNEN ML , Maas HA, van de Schans SA, Coebergh JW, et al
    Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it?
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. GAZDAR AF
    Should we continue to use the term non-small-cell lung cancer?
    Ann Oncol. 2010;21 Suppl 7:vii225-vii229.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. KONOPA K
    Do we have markers to select patients for adjuvant therapies of non-small-cell lung cancer?
    Ann Oncol. 2010;21 Suppl 7:vii199-vii202.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. LE CHEVALIER T
    Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?
    Ann Oncol. 2010;21 Suppl 7:vii196-vii198.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. VANSTEENKISTE J , Dooms C, De Leyn P
    Early stage non-small-cell lung cancer: challenges in staging and adjuvant treatment: evidence-based staging.
    Ann Oncol. 2010;21 Suppl 7:vii189-vii195.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. YASUKAWA M , Ochi T, Fujiwara H
    Relapse of renal cell carcinoma with disappearance of HLA class I following hTERT peptide vaccination.
    Ann Oncol. 2010;21:2122-4.
    PubMed     Text format     Related articles   
    
    
    
    
45. SEIDEL C , Janssen S, Karstens JH, Welte T, et al
    Recall pneumonitis during systemic treatment with sunitinib.
    Ann Oncol. 2010;21:2119-20.
    PubMed     Text format     Related articles   
    
    
    
    
46. CHUA TC , Sarkar A, Saxena A, Glenn D, et al
    Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients.
    Ann Oncol. 2010;21:2017-22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. EL-RAYES BF , Zalupski M, Bekai-Saab T, Heilbrun LK, et al
    A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.
    Ann Oncol. 2010;21:1999-2004.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
48. KOSMIDIS PA , Fountzilas G, Eleftheraki AG, Kalofonos HP, et al
    Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. JOERGER M , Matter-Walstra K, Fruh M, Kuhnel U, et al
    Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. DAHABREH IJ , Linardou H, Kosmidis P, Bafaloukos D, et al
    EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. SMITH IE , Pierga JY, Biganzoli L, Cortes-Funes H, et al
    First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. RUGGERI EM , Cecere FL, Moscetti L, Doni L, et al
    Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.
    Ann Oncol. 2010;21:1926-7.
    PubMed     Text format     Related articles   
    
    
    
    August 2010
53. DINGEMANS AM , de Langen AJ, van den Boogaart V, Marcus JT, et al
    First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. FUJIWARA Y , Hotta K, Di Maio M, Kiura K, et al
    Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. SENAN S , Cardenal F, Vansteenkiste J, Stigt J, et al
    A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
56. BOYLE P , Chapman CJ, Holdenrieder S, Murray A, et al
    Clinical validation of an autoantibody test for lung cancer.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
57. FERTE C , Besse B, Dansin E, Parent F, et al
    Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.
    Ann Oncol. 2010;21:1385-7.
    PubMed     Text format     Related articles   
    
    
    
    
58. PENEL N , Italiano A, Isambert N, Bompas E, et al
    Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy.
    Ann Oncol. 2010;21:1361-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
59. HASHIMOTO K , Yonemori K, Katsumata N, Shimizu C, et al
    Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy.
    Ann Oncol. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. ITALIANO A , Delcambre C, Hostein I, Cazeau AL, et al
    Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
    Ann Oncol. 2010;21:1135-7.
    PubMed     Text format     Related articles   
    
    
    
    
61. IZARZUGAZA MI , Ardanaz E, Chirlaque MD, Font C, et al
    Tobacco-related tumours of the lung, bladder and larynx: changes in Spain.
    Ann Oncol. 2010;21 Suppl 3:iii52-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
62. CABANES A , Vidal E, Aragones N, Perez-Gomez B, et al
    Cancer mortality trends in Spain: 1980-2007.
    Ann Oncol. 2010;21 Suppl 3:iii14-20.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2009
63. KOZLOFF M , Chuang E, Starr A, Gowland PA, et al
    An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
    Ann Oncol. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: